---
figid: PMC7024330__molecules-25-00358-g002
figtitle: AR signaling pathway and targeted therapeutic strategies against AR
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
pmcid: PMC7024330
filename: molecules-25-00358-g002.jpg
figlink: pmc/articles/PMC7024330/figure/molecules-25-00358-f002/
number: F2
caption: 'AR signaling pathway and targeted therapeutic strategies against AR. AR
  can regulate the proliferation, migration, and invasiveness in BC through genomic
  and/or nongenomic pathways. CYP17A1 is the enzyme that converts androgen precursors
  into DHEA, HSD3β1 catalyzes DHEA to AD, while AKR1C3 converts AD to testosterone;
  finally, testosterone is catalyzed to DHT by 5α-reductase. In the genomic way of
  AR activation, DHT binds and activates AR, which disassociates from heat shock proteins
  and forms dimers, which translocate to the nucleus, where gene transcription is
  modulated by binding to the androgen response elements of target genes. In the nongenomic
  way of AR activation, ERK-mediated AR signaling involves phosphoinositide 3-kinase
  (PI3K), Src proteins, and Ras GTPase. Abiraterone acetate selectively and irreversibly
  blocks CYP17A1 activity. Drugs: Seviteronel is a CYP17A1 inhibitor. Bicalutamide
  is a first-generation and Enzalutamide a second-generation AR antagonist that blocks
  androgens binding to AR. Enzalutamide also inhibits AR nuclear translocation and
  AR-mediated transcription. In the nongenomic way of AR activation, the use of AR
  antagonists/inhibitors of AR-activated proteins that disrupts the AR/src association
  could be a starting point to reduce BC cell proliferation. Abbreviations: AD—androstenedione;
  AKR1C3—aldo-keto reductase family 1 member C3; AP—androgen precursors; AR—androgen
  receptor; ARE—androgen receptor element; CYP17A1—cytochrome P450 c17; DHEA—dehydroepiandrosterone;
  DHT—dihydrotestosterone; HSP—heat shock protein; HSD3β1—human 3-beta-hydroxysteroid
  dehydroxynase/delta5-4 isomerase type 1; T—testosterone; TF—transcription factor.'
papertitle: Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights.
reftext: Aristomenis Anestis, et al. Molecules. 2020 Jan;25(2):358.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9626089
figid_alias: PMC7024330__F2
figtype: Figure
redirect_from: /figures/PMC7024330__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7024330__molecules-25-00358-g002.html
  '@type': Dataset
  description: 'AR signaling pathway and targeted therapeutic strategies against AR.
    AR can regulate the proliferation, migration, and invasiveness in BC through genomic
    and/or nongenomic pathways. CYP17A1 is the enzyme that converts androgen precursors
    into DHEA, HSD3β1 catalyzes DHEA to AD, while AKR1C3 converts AD to testosterone;
    finally, testosterone is catalyzed to DHT by 5α-reductase. In the genomic way
    of AR activation, DHT binds and activates AR, which disassociates from heat shock
    proteins and forms dimers, which translocate to the nucleus, where gene transcription
    is modulated by binding to the androgen response elements of target genes. In
    the nongenomic way of AR activation, ERK-mediated AR signaling involves phosphoinositide
    3-kinase (PI3K), Src proteins, and Ras GTPase. Abiraterone acetate selectively
    and irreversibly blocks CYP17A1 activity. Drugs: Seviteronel is a CYP17A1 inhibitor.
    Bicalutamide is a first-generation and Enzalutamide a second-generation AR antagonist
    that blocks androgens binding to AR. Enzalutamide also inhibits AR nuclear translocation
    and AR-mediated transcription. In the nongenomic way of AR activation, the use
    of AR antagonists/inhibitors of AR-activated proteins that disrupts the AR/src
    association could be a starting point to reduce BC cell proliferation. Abbreviations:
    AD—androstenedione; AKR1C3—aldo-keto reductase family 1 member C3; AP—androgen
    precursors; AR—androgen receptor; ARE—androgen receptor element; CYP17A1—cytochrome
    P450 c17; DHEA—dehydroepiandrosterone; DHT—dihydrotestosterone; HSP—heat shock
    protein; HSD3β1—human 3-beta-hydroxysteroid dehydroxynase/delta5-4 isomerase type
    1; T—testosterone; TF—transcription factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ad
  - Hsd3b1
  - Cyp17a1
  - ap
  - Ar
  - Pik3r1
  - Src
  - Akt1
  - Arp
  - Rere
  - Ephb2
  - Mapk1
  - Afg3l2
  - Alpha-re
  - AKR1C3
  - HSD3B1
  - CYP17A1
  - AR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SRC
  - FGR
  - FYN
  - YES1
  - AKT1
  - AKT2
  - AKT3
  - HSP90B2P
  - CRISP1
  - RERE
  - MANF
  - ARFRP1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - NR1I2
  - JTB
  - TF
  - DHEA
  - Abiraterone
  - Enzalutamide
---
